Home FDA labels 15ca2fd8-a7fa-6460-e063-6294a90aa9a5 FDA label 15ca2fd8-a7fa-6460-e063-6294a90aa9a5 openFDA label record# This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)
SPL set ID f4a3ff3a-fb49-4901-afdc-92723d7902ee
SPL ID 15ca2fd8-a7fa-6460-e063-6294a90aa9a5
Version 6
Effective date 2024-04-10
Source export date 2026-09-28
Source partition 6
Source file https://download.open.fda.gov/drug/label/drug-label-0006-of-0014.json.zip
Source object key raw/openfda/drug-label/2026-09-28/e0861bcde1444ef952820955caafc6f3fd29783e5ade07a13d933aa3336b399f/drug-label-0006-of-0014.json.zip
Source manifest SHA-256 cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
Import run 20260929T050834Z
Imported at 2026-09-29 05:39:18 Harmonized identifier links# Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
Harmonized identifiers page 1 of 1 · 2 matching rows.
Warnings cross-check# openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Warnings sections page 1 of 1 · 1 matching rows.
warnings and cautions 5 WARNINGS AND PRECAUTIONS Excessive administration of vitamin D compounds, including Paricalcitol Capsules, can cause over suppression of PTH, hypercalcemia, hypercalciuria, hyperphosphatemia, and adynamic bone disease. Hypercalcemia: Excessive administration of Paricalcitol Capsules can cause over suppression of PTH, hypercalcemia, hypercalciuria, hyperphosphatemia, and adynamic bone disease. Prescription-based doses of vitamin D and its derivatives should be withheld during Paricalcitol treatment ( 5.1 ). Digitalis toxicity: Potentiated by hypercalcemia of any cause. Use caution when Paricalcitol Capsules are prescribed concomitantly with digitalis compounds ( 5.2 ). Laboratory tests: Monitor serum calcium, serum phosphorus, and serum or plasma iPTH during initial dosing or following any dose adjustment. Paricalcitol Capsules may increase serum creatinine and therefore decrease the estimated GFR (eGFR) ( 5.3 ). Aluminum overload and toxicity: Avoid excessive use of aluminum containing compounds ( 5.4 ). 5.1 Hypercalcemia Progressive hypercalcemia due to overdosage of vitamin D and its metabolites may be so severe as to require emergency attention [see Overdosage (10) ]. Acute hypercalcemia may exacerbate tendencies for cardiac arrhythmias and seizures and may potentiate the action of digitalis. Chronic hypercalcemia can lead to generalized vascular calcification and other soft-tissue calcification. Concomitant administration of high doses of calcium-containing preparations or thiazide diueretics with Paricalcitol may increase the risk of hypercalcemia. High intake of calcium and phosphate concomitant with vitamin D compounds may lead to serum abnormalities requiring more frequent patient monitoring and individualized dose titration. Patients also should be informed about the symptoms of elevated calcium, which include feeling tired, difficulty thinking clearly, loss of appetite, nausea, vomiting, constipation, increased thirst, increased urination and weight loss. Prescription-based doses of vitamin D and its derivatives should be withheld during Paricalcitol treatment to avoid hypercalcemia. 5.2 Digitalis Toxicity Digitalis toxicity is potentiated by hypercalcemia of any cause. Use caution when Paricalcitol Capsules are prescribed concomitantly with digitalis compounds. 5.3 Laboratory Tests During the initial dosing or following any dose adjustment of medication, serum calcium, serum phosphorus, and serum or plasma iPTH should be monitored at least every two weeks for 3 months, then monthly for 3 months, and every 3 months thereafter.During the initial dosing or following any dose adjustment of medication, serum calcium, serum phosphorus, and serum or plasma iPTH should be monitored at least every two weeks for 3 months, then monthly for 3 months, and every 3 months thereafter. In pre-dialysis patients, Paricalcitol Capsules may increase serum creatinine and therefore decrease the estimated GFR (eGFR). Similar effects have also been seen with calcitriol. 5.4 Aluminum Overload and Toxicity Aluminum-containing preparations (e.g., antacids, phosphate binders) should not be administered chronically with Paricalcitol, as increased blood levels of aluminum and aluminum bone toxicity may occur.
Adverse reactions cross-check# openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Adverse reactions sections page 1 of 1 · 3 matching rows.
adverse reactions 6 ADVERSE REACTIONS Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. The most common adverse reactions (> 5% and more frequent than placebo) include diarrhea, hypertension, dizziness and vomiting. To report SUSPECTED ADVERSE REACTIONS, contact ECI Pharmaceuticals, LLC at 954-486-8181 X-109 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience CKD Stages 3 and 4 The safety of Paricalcitol Capsules has been evaluated in three 24-week (approximately six-month), double-blind, placebo-controlled, multicenter clinical studies involving 220 CKD Stages 3 and 4 patients. Six percent (6%) of Paricalcitol Capsules treated patients and 4% of placebo treated patients discontinued from clinical studies due to an adverse event. Adverse events occurring in the Paricalcitol Capsules group at a frequency of 2% or greater and more frequently than in the placebo group are presented in Table 1: Table 1: Treatment-Emergent Adverse Events by Body System Occurring in ≥ 2% of Subjects in the Paricalcitol-Treated Group of Three, Double-Blind, Placebo-Controlled, Phase 3, CKD Stages 3 and 4 Studies; All Treated Patients Number (%) of Subjects Adverse Event Includes only events more common in the Paricalcitol treatment group. Paricalcitol Capsules (n=107) Placebo (n=113) Overall 88 (82%) 86 (76%) Ear and Labyrinth Disorders Vertigo 5 (4.7%) 0 (0.0%) Gastrointestinal Disorders Abdominal Discomfort 4 (3.7%) 1 (0.9%) Constipation 4 (3.7%) 4 (3.5%) Diarrhea 7 (6.5%) 5 (4.4%) Nausea 6 (5.6%) 4 (3.5%) Vomiting 5 (4.7%) 5 (4.4%) General Disorders and Administration Site Conditions Chest Pain 3 (2.8%) 1 (0.9%) Edema 6 (5.6%) 5 (4.4%) Pain 4 (3.7%) 4 (3.5%) Immune System Disorders Hypersensitivity 6 (5.6%) 2 (1.8%) Infections and Infestations Fungal Infection 3 (2.8%) 0 (0.0%) Gastroenteritis 3 (2.8%) 3 (2.7%) Infection 3 (2.8%) 3 (2.7%) Sinusitis 3 (2.8%) 1 (0.9%) Urinary Tract Infection 3 (2.8%) 1 (0.9%) Viral Infection 8 (7.5%) 8 (7.1%) Metabolism and Nutrition Disorders Dehydration 3 (2.8%) 1 (0.9%) Musculoskeletal and Connective Tissue Disorders Arthritis 5 (4.7%) 0 (0.0%) Back Pain 3 (2.8%) 1 (0.9%) Muscle Spasms 3 (2.8%) 0 (0.0%) Nervous System Disorders Dizziness 5 (4.7%) 5 (4.4%) Headache 5 (4.7%) 5 (4.4%) Syncope 3 (2.8%) 1 (0.9%) Psychiatric Disorders Depression 3 (2.8%) 0 (0.0%) Respiratory, Thoracic and Mediastinal Disorders Cough 3 (2.8%) 2 (1.8%) Oropharyngeal Pain 4 (3.7%) 0 (0.0%) Skin and Subcutaneous Tissue Disorders Pruritus 3 (2.8%) 3 (2.7%) Rash 4 (3.7%) 1 (0.9%) Skin Ulcer 3 (2.8%) 0 (0.0%) Vascular Disorders Hypertension 7 (6.5%) 4 (3.5%) Hypotension 5 (4.7%) 3 (2.7%) The following adverse reactions, with a causal relationship to Paricalcitol, occurred in <2% of the Paricalcitol treated patients in the above double-blind, placebo-controlled clinical trial data set. Gastrointestinal Disorders: Dry mouth Investigations: Hepatic enzyme abnormal Nervous System Disorders : Dysgeusia Skin and Subcutaneous Tissue Disorders: Urticaria CKD Stage 5 The safety of Paricalcitol Capsules has been evaluated in one 12-week, double-blind, placebo-controlled, multicenter clinical study involving 88 CKD Stage 5 patients. Sixty-one patients received Paricalcitol Capsules and 27 patients received placebo. The proportion of patients who terminated prematurely from the study due to adverse events was 7% for Paricalcitol Capsules treated patients and 7% for placebo patients. Adverse events occurring in the Paricalcitol Capsules group at a frequency of 2% or greater and more frequently than in the placebo group are as follows: Table 2. Treatment-Emergent Adverse Events by Body System Occurring in ≥ 2% of Subjects in the Paricalcitol-Treated Group, Double- Blind, Placebo-Controlled, Phase 3, CKD Stage 5 Study; All Treated Patients Number (%) of Subjects Adverse Events Includes only events more common in the Paricalcitol treatment group. Paricalcitol Capsules (n=61) Placebo (n=27) Overall 43 (70%) 19 (70%) Gastrointestinal Disorders Constipation 3 (4.9%) 0 (0.0%) Diarrhea 7 (11.5%) 3 (11.1%) Vomiting 4 (6.6%) 0 (0.0%) General Disorders and Administration Site Conditions Fatigue 2 (3.3%) 0 (0.0%) Edema Peripheral 2 (3.3%) 0 (0.0%) Infections and Infestations Nasopharyngitis 5 (8.2%) 2 (7.4%) Peritonitis 3 (4.9%) 0 (0.0%) Sinusitis 2 (3.3%) 0 (0.0%) Urinary Tract Infection 2 (3.3%) 0 (0.0%) Metabolism and Nutrition Disorders Fluid Overload 3 (4.9%) 0 (0.0%) Hypoglycemia 2 (3.3%) 0 (0.0%) Nervous System Disorders Dizziness 4 (6.6%) 0 (0.0%) Headache 2 (3.3%) 0 (0.0%) Psychiatric Disorders Anxiety 2 (3.3%) 0 (0.0%) Insomnia 3 (4.9%) 0 (0.0%) Renal and Urinary Disorders Renal Failure Chronic 2 (3.3%) 0 (0.0%) The following adverse reactions, with a causal relationship to Paricalcitol, occurred in <2% of the Paricalcitol treated patients in the above double-blind, placebo-controlled clinical trial data set. Gastrointestinal Disorders: Gastroesophageal reflux disease Metabolism and Nutrition Disorders: Decreased appetite, hypercalcemia, hypocalcemia Reproductive System and Breast Disorders: Breast tenderness Skin and Subcutaneous Tissue Disorders: Acne 6.2 Postmarketing Experience The following additional adverse reactions have been reported during post-approval use and post-approval clinical trials with the active ingredient in Paricalcitol Capsules: Immune System Disorders: Angioedema (including laryngeal edema) Metabolism and Nutrition Disorders: Hypercalcemia Investigations: Blood creatinine increased
adverse reactions table <table frame="void" border="1" width="652"><caption> Table 1: Treatment-Emergent Adverse Events by Body System Occurring in ≥ 2% of Subjects in the Paricalcitol-Treated Group of Three, Double-Blind, Placebo-Controlled, Phase 3, CKD Stages 3 and 4 Studies; All Treated Patients</caption><tbody><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" colspan="4" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">Number (%) of Subjects</content></td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">Adverse Event </content><footnote ID="FNa5b91a8a-57d7-4019-8663-4f54187f280e"> Includes only events more common in the Paricalcitol treatment group.</footnote></td><td align="center" colspan="2" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">Paricalcitol Capsules</content><content styleCode="bold">(n=107)</content></td><td align="center" colspan="2" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">Placebo</content><content styleCode="bold">(n=113)</content></td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">Overall </content></td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">88</content></td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">(82%)</content></td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">86</content></td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">(76%)</content></td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">Ear and Labyrinth Disorders</content></td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Vertigo </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">5 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(4.7%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(0.0%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">Gastrointestinal Disorders</content></td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Abdominal Discomfort </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">4 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(3.7%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">1 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(0.9%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Constipation </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">4 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(3.7%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">4 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(3.5%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Diarrhea </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">7 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(6.5%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">5 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(4.4%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Nausea </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">6 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(5.6%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">4 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(3.5%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Vomiting </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">5 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(4.7%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">5 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(4.4%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">General Disorders and Administration Site Conditions</content></td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Chest Pain </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">3 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(2.8%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">1 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(0.9%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Edema </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">6 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(5.6%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">5 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(4.4%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Pain </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">4 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(3.7%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">4 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(3.5%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">Immune System Disorders</content></td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Hypersensitivity </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">6 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(5.6%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">2 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(1.8%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">Infections and Infestations</content></td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Fungal Infection </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">3 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(2.8%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(0.0%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Gastroenteritis </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">3 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(2.8%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">3 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(2.7%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Infection </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">3 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(2.8%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">3 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(2.7%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Sinusitis </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">3 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(2.8%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">1 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(0.9%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Urinary Tract Infection </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">3 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(2.8%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">1 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(0.9%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Viral Infection </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">8 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(7.5%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">8 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(7.1%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">Metabolism and Nutrition Disorders</content></td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Dehydration </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">3 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(2.8%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">1 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(0.9%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">Musculoskeletal and Connective Tissue Disorders</content></td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Arthritis </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">5 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(4.7%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(0.0%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Back Pain </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">3 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(2.8%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">1 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(0.9%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Muscle Spasms </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">3 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(2.8%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(0.0%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">Nervous System Disorders</content></td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Dizziness </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">5 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(4.7%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">5 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(4.4%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Headache </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">5 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(4.7%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">5 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(4.4%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Syncope </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">3 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(2.8%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">1 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(0.9%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">Psychiatric Disorders</content></td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Depression </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">3 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(2.8%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(0.0%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">Respiratory, Thoracic and Mediastinal Disorders</content></td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Cough </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">3 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(2.8%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">2 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(1.8%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Oropharyngeal Pain </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">4 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(3.7%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(0.0%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">Skin and Subcutaneous Tissue Disorders</content></td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Pruritus </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">3 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(2.8%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">3 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(2.7%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Rash </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">4 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(3.7%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">1 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(0.9%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Skin Ulcer </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">3 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(2.8%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(0.0%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">Vascular Disorders</content></td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Hypertension </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">7 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(6.5%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">4 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(3.5%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Hypotension </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">5 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(4.7%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">3 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(2.7%) </td></tr></tbody></table>
adverse reactions table <table frame="void" border="1" width="579"><caption> Table 2. Treatment-Emergent Adverse Events by Body System Occurring in ≥ 2% of Subjects in the Paricalcitol-Treated Group, Double- Blind, Placebo-Controlled, Phase 3, CKD Stage 5 Study; All Treated Patients</caption><tbody><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" colspan="4" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">Number (%) of Subjects</content></td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">Adverse Events</content><content styleCode="bold"><sup/></content><footnote ID="FN857c48d1-21cf-415c-8fd4-7a4d868b8eb4">Includes only events more common in the Paricalcitol treatment group. </footnote></td><td align="center" colspan="2" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">Paricalcitol Capsules</content><content styleCode="bold">(n=61)</content></td><td align="center" colspan="2" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">Placebo</content><content styleCode="bold">(n=27)</content></td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">Overall </content></td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">43</content></td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">(70%)</content></td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">19</content></td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">(70%)</content></td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">Gastrointestinal Disorders</content></td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Constipation </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">3 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(4.9%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(0.0%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Diarrhea </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">7 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(11.5%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">3 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(11.1%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Vomiting </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">4 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(6.6%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(0.0%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">General Disorders and Administration Site Conditions</content></td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Fatigue </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">2 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(3.3%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(0.0%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Edema Peripheral </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">2 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(3.3%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(0.0%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">Infections and Infestations</content></td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Nasopharyngitis </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">5 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(8.2%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">2 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(7.4%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Peritonitis </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">3 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(4.9%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(0.0%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Sinusitis </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">2 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(3.3%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(0.0%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Urinary Tract Infection </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">2 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(3.3%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(0.0%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">Metabolism and Nutrition Disorders</content></td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Fluid Overload </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">3 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(4.9%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(0.0%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Hypoglycemia </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">2 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(3.3%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(0.0%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">Nervous System Disorders</content></td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Dizziness </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">4 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(6.6%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(0.0%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Headache </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">2 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(3.3%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(0.0%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">Psychiatric Disorders</content></td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Anxiety </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">2 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(3.3%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(0.0%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Insomnia </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">3 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(4.9%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(0.0%) </td></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"><content styleCode="bold">Renal and Urinary Disorders</content></td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top"/></tr><tr><td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Renal Failure Chronic </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">2 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(3.3%) </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">0 </td><td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="top">(0.0%) </td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.